J E Green

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc miRNA signature associated with outcome of gastric cancer patients following chemotherapy
    Chang Hee Kim
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med Genomics 4:79. 2011
  2. pmc Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models
    Christina N Bennett
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Breast Cancer Res 10:213. 2008
  3. pmc Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection
    Hark Kyun Kim
    National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med Genomics 4:48. 2011
  4. pmc Three microarray platforms: an analysis of their concordance in profiling gene expression
    David Petersen
    Advanced Technology Center, Center for Cancer Research, National Cancer Institute, Gaithersburg, MD 20877, USA
    BMC Genomics 6:63. 2005
  5. ncbi request reprint Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM
    Jeffrey E Green
    Laboratory of Cellular Regulation and Carcinogenesis, National Cancer Institute, Building 41, Bethesda, MD 20892, USA
    Transgenic Res 11:635-6. 2002
  6. pmc Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage
    Min Zhu
    Transgenic Oncogenesis and Genomics Section, Laboratory of Cell Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Genome Biol 12:R77. 2011
  7. ncbi request reprint 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice
    J E Green
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 61:7449-55. 2001
  8. ncbi request reprint Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy
    Jeffrey E Green
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 10:385S-90S. 2004
  9. ncbi request reprint Application of gene expression profiling for validating models of human breast cancer
    Jeffrey E Green
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Toxicol Pathol 32:84-9. 2004
  10. pmc Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage
    M A Shibata
    Laboratory of Cell Regulation and Carcinogenesis, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    EMBO J 18:2692-701. 1999

Collaborators

Detail Information

Publications66

  1. pmc miRNA signature associated with outcome of gastric cancer patients following chemotherapy
    Chang Hee Kim
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med Genomics 4:79. 2011
    ..In order to identify miRNA signatures for gastric cancer and for predicting clinical resistance to cisplatin/fluorouracil (CF) chemotherapy, a comprehensive miRNA microarray analysis was performed using endoscopic biopsy samples...
  2. pmc Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models
    Christina N Bennett
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Breast Cancer Res 10:213. 2008
    ....
  3. pmc Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection
    Hark Kyun Kim
    National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med Genomics 4:48. 2011
    ....
  4. pmc Three microarray platforms: an analysis of their concordance in profiling gene expression
    David Petersen
    Advanced Technology Center, Center for Cancer Research, National Cancer Institute, Gaithersburg, MD 20877, USA
    BMC Genomics 6:63. 2005
    ..As part of a validation study for the long oligonucleotide arrays, we compared and contrasted expression profiles from the three formats, testing RNA from six different cell lines against a universal reference standard...
  5. ncbi request reprint Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM
    Jeffrey E Green
    Laboratory of Cellular Regulation and Carcinogenesis, National Cancer Institute, Building 41, Bethesda, MD 20892, USA
    Transgenic Res 11:635-6. 2002
  6. pmc Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage
    Min Zhu
    Transgenic Oncogenesis and Genomics Section, Laboratory of Cell Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Genome Biol 12:R77. 2011
    ....
  7. ncbi request reprint 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice
    J E Green
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 61:7449-55. 2001
    ..The tumor-inhibitory effects of DHEA and DFMO on mammary cancer growth appear to occur after the development of preinvasive lesions, suggesting that these agents inhibit tumor progression but not initiation...
  8. ncbi request reprint Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy
    Jeffrey E Green
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 10:385S-90S. 2004
    ....
  9. ncbi request reprint Application of gene expression profiling for validating models of human breast cancer
    Jeffrey E Green
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Toxicol Pathol 32:84-9. 2004
    ..These approaches have led to new insights into molecular pathways involved in oncogenesis, new classifications of human breast cancer, and the identification of new genes that may be relevant to understanding and treating human cancer...
  10. pmc Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage
    M A Shibata
    Laboratory of Cell Regulation and Carcinogenesis, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    EMBO J 18:2692-701. 1999
    ....
  11. ncbi request reprint Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice
    I G Maroulakou
    Laboratory of Chemoprevention, National Cancer Institute, Bethesda, MD 20892, USA
    Mol Carcinog 20:168-74. 1997
    ..Functional loss of p53 and not p53 mutations participates in TAG-induced mammary carcinoma development and progression...
  12. ncbi request reprint Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer
    K V Desai
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH, Building 41, Room C629, 41 Library Dr, Bethesda, Maryland 20892, USA
    Endocr Relat Cancer 9:207-20. 2002
    ....
  13. pmc Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer
    M J Hoenerhoff
    Transgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 4054, Bethesda, MD 20892, USA
    Transgenic Res 20:247-59. 2011
    ..Further development of a C3(1)SV40 T/t-antigen based model could establish valuable transgenic rat lines that develop basal-type mammary tumors...
  14. pmc Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis
    A Calvo
    Laboratory of Cancer Biology and Genetics, NCI, NIH, Bethesda, MD 20892, USA
    Oncogene 27:5373-84. 2008
    ..The TNC signaling pathway plays an important role in mammary tumor growth and metastases, suggesting that TNC may be a relevant target for therapy against metastatic breast cancer...
  15. ncbi request reprint Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice
    M L Liu
    Laboratory of Cell Regulation and Carcinogenesis, Division of Basic Sciences, National Cancer Institute, National Institute of Health, Bethesda, Maryland, MD 20892, USA
    Oncogene 20:2044-9. 2001
    ..These data strongly suggest that the gene dosage of Ki-ras affects tumor promotion at an early stage of mammary tumor progression in this SV40 Tag-induced model of mammary oncogenesis...
  16. ncbi request reprint Pre-clinical applications of transgenic mouse mammary cancer models
    C J Kavanaugh
    Laboratory of Cellular Regulation and Carcinogenesis, National Cancer Institute, Building 41, Bethesda, MD 20892, USA
    Transgenic Res 11:617-33. 2002
    ....
  17. ncbi request reprint Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21
    M A Shibata
    Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Gene Ther 8:23-35. 2001
    ..Because reduced p21 expression occurs frequently in human breast cancer, restoration of the Cdk inhibitor p21 by gene therapy approaches may provide a method for inhibiting mammary tumor progression...
  18. ncbi request reprint p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma
    M A Shibata
    Laboratory of Molecular Oncology, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Cancer Res 56:2998-3003. 1996
    ....
  19. ncbi request reprint Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron I
    C L Jorcyk
    Laboratory of Molecular Oncology, National Cancer Institute, FCRDC, Frederick, MD 21702 1201, USA
    Cell Mol Biol (Noisy-le-grand) 43:211-25. 1997
    ..Further characterization of the vascular-specific element contained within intron I will provide important insights into the mechanisms controlling gene expression during angiogenesis...
  20. ncbi request reprint Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithe
    J M Wigginton
    Pediatric Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 166:1156-68. 2001
    ..The results also demonstrate that these mechanisms are active against established tumor as well as developing preneoplastic lesions...
  21. ncbi request reprint Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling
    Alexander N Shoushtari
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Breast Dis 28:39-51. 2007
    ..Together, these advances offer a framework for classifying human tumors, identifying appropriate GEM models for specific experimental purposes, and utilizing the combined data to identify more specific and effective cancer therapies...
  22. ncbi request reprint Interrogating mouse mammary cancer models: insights from gene expression profiling
    Antonio A Fargiano
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Mammary Gland Biol Neoplasia 8:321-34. 2003
    ....
  23. ncbi request reprint Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis
    Kristin K Deeb
    Laboratory of Cell Regulation and Carcinogenesis, National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA
    Cancer Res 67:8065-80. 2007
    ....
  24. ncbi request reprint Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease
    Ting Hu Qiu
    Laboratory of Cell Regulation and Carcinogenesis, Cancer Research Center, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 64:5973-81. 2004
    ..These results demonstrate that the genetic analysis of mouse models of tumorigenesis may be highly relevant to human cancer and that the metastatic phenotype of a tumor may be affected by the germline genetic configuration of the host...
  25. pmc BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases
    M J Hoenerhoff
    Transgenic Oncogenesis Group, Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20982, USA
    Oncogene 28:3022-32. 2009
    ..In summary, BMI1 collaborates with H-RAS to induce an aggressive and metastatic phenotype with the unusual occurrence of brain metastasis, making it an important target for diagnosis and treatment of aggressive breast cancer...
  26. ncbi request reprint The promise of genetically engineered mice for cancer prevention studies
    Jeffrey E Green
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Besthesda, MD 20892, USA
    Nat Rev Cancer 5:184-98. 2005
    ..The validation of such models for chemoprevention will help the selection of appropriate agents for large-scale clinical trials and allow the testing of combination therapies...
  27. pmc Initiating oncogenic event determines gene-expression patterns of human breast cancer models
    Kartiki V Desai
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:6967-72. 2002
    ..Moreover, similarities in gene expression between human breast cancers and the mouse models have been identified, thus providing an important component for the validation of transgenic mammary cancer models...
  28. ncbi request reprint Effects of pooling mRNA in microarray class comparisons
    Joanna H Shih
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Bioinformatics 20:3318-25. 2004
    ....
  29. pmc GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells
    I M Chu
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA
    Oncogene 31:2017-27. 2012
    ..Induction of GATA3 in BTNBC cells or novel approaches that inhibit LOX expression or activity could be important strategies for treating BTNBCs...
  30. ncbi request reprint Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice
    J E Green
    Laboratory of Molecular Virology, National Cancer Institute, Bethesda, Maryland 20892
    Nature 341:72-4. 1989
    ..Mice with an HTLV-1 tax transgene might be a useful model for studying the development of Sjögren-syndrome-like pathology...
  31. ncbi request reprint The use of genetically altered mice for breast cancer prevention studies
    Claudine Kavanaugh
    Laboratory of Cellular Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 133:2404S-2409S. 2003
    ..The application of gene expression profiling to chemopreventive studies will aid in the selection of appropriate models for preclinical testing and further define mechanisms of action...
  32. ncbi request reprint Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate
    Kartiki V Desai
    Laboratory of Cell Regulation and Carcinogenesis, 41 Medlar s Drive, Room C619, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Endocrinol 18:2895-907. 2004
    ..The VP castration model exhibits immune cell infiltration and loss of PTEN that is often observed in progressive PCa, thereby making this model useful for further delineation of androgen-regulated gene expression with relevance to PCa...
  33. pmc Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
    H K Kim
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Pharmacogenomics J 12:119-27. 2012
    ..026). Thus, combined expression of MYC, EGFR and FGFR2 is predictive of poor survival in CF-treated metastatic gastric cancer patients...
  34. pmc A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression
    S J Kaczmarczyk
    Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD 20892, USA
    Nucleic Acids Res 29:E56-6. 2001
    ..This approach can be applied to targeting strategies for generating genetically altered mice and gene therapy...
  35. ncbi request reprint Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms
    Jung im Huh
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Oncogene 24:790-800. 2005
    ....
  36. ncbi request reprint Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors
    Yiping Wu
    Section on Cellular and Molecular Physiology, Diabetes Branch, National Institute of Diabetes, Digestive and Kidney Diseases NIH, Building 10, Bethesda, MD 20892, USA
    Cancer Res 63:4384-8. 2003
    ..Our data demonstrate that circulating IGF-I levels play a significant role as a risk factor in the onset and development of mammary tumors in two well-established animal models of breast cancer...
  37. ncbi request reprint Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression
    Jung im Huh
    Laboratory of Cell Regulation and Carcinogenesis, Building 41, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 66:3495-503. 2006
    ..Although 2ME(2) significantly reduced tumor growth at late stages, these results also suggest that altered tumor morphology and accelerated tumor growth may occur if 2ME(2) is administered in a prevention setting for prolonged periods...
  38. pmc Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer
    Christina N Bennett
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Toxicol Pathol 38:88-95. 2010
    ....
  39. ncbi request reprint Prostate cancer and the genomic revolution: Advances using microarray analyses
    Alfonso Calvo
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH, Building 41, Bethesda, MD 20892, USA
    Mutat Res 576:66-79. 2005
    ..Not only will the "omic" revolution change basic science, but it will lead to a new era of molecular medicine...
  40. ncbi request reprint Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors
    Alfonso Calvo
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute NIH, Building 41, Room C629, 41 Library Drive, Bethesda, MD 20892, USA
    Cancer Res 62:5325-35. 2002
    ..This work demonstrates that expression profiling in animal models may lead to the identification of novel genes involved in human prostate cancer biology...
  41. ncbi request reprint Isolation and characterization of a novel gene expressed in multiple cancers
    S L Chen
    Laboratory of Molecular Oncology, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Oncogene 12:741-51. 1996
    ..Taken together, these results suggest that N8 may play different roles during embryogenesis and in the adult animals...
  42. pmc Modeling metastasis biology and therapy in real time in the mouse lung
    Arnulfo Mendoza
    Tumor and Metastasis Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:2979-88. 2010
    ..We believe that this assay system is uniquely capable of advancing our understanding of both metastasis biology and therapeutic strategies...
  43. ncbi request reprint Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis
    Carolyn J M Best
    Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Diagn Mol Pathol 12:63-70. 2003
    ..We suggest that these data provide insight into the molecular nature of clinically aggressive prostate cancer...
  44. ncbi request reprint Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice
    Alfonso Calvo
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:3934-8. 2002
    ..Our results demonstrate that the adenoviral induction of high levels of circulating endostatin significantly inhibits mammary tumor growth during the period when the "angiogenic switch" occurs...
  45. ncbi request reprint Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin
    Alfonso Calvo
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Int J Cancer 101:224-34. 2002
    ..These results demonstrate that P125A endostatin inhibits the angiogenic switch during mammary gland adenocarcinoma tumor progression in the C3(1)/Tag transgenic model...
  46. ncbi request reprint Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin
    Oscar Gonzalez-Moreno
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 114:870-8. 2005
    ..This study describes a novel AM-induced mechanism of tumor sensitization through the upregulation of functional IL-13R alpha 2 chain, an ideal target for the highly specific recombinant chimeric cytotoxin IL13-PE38...
  47. doi request reprint Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy
    Bharat H Joshi
    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 68:9311-7. 2008
    ....
  48. pmc Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry
    Hark Kyun Kim
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Proteome Res 9:4123-30. 2010
    ..Thus, protein profiles obtained from endoscopic biopsy samples may be useful in assisting with the diagnosis of gastric cancer and, possibly, in identifying early stage disease...
  49. ncbi request reprint Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms
    Tamaro S Hudson
    Laboratory of Cellular Regulation and Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Res 67:8396-405. 2007
    ....
  50. pmc Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment
    Dalit Barkan
    Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA
    Cancer Res 70:5706-16. 2010
    ..Thus, inhibiting Col-I production, its interaction with beta1-integrin, and downstream signaling of beta1-integrin may be important strategies for preventing or treating recurrent metastatic disease...
  51. ncbi request reprint 2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice
    Jung im Huh
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Building 41, 41 Medlars Drive, Bethesda, MD 20892, USA
    Endocrinology 148:1266-77. 2007
    ..These data demonstrate that 2ME(2) can induce a partial differentiation of the mammary gland through mechanisms that differ from those normally used during pregnancy...
  52. pmc Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
    Jason I Herschkowitz
    Lineberger Comprehensive Cancer Center
    Genome Biol 8:R76. 2007
    ..To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors...
  53. ncbi request reprint Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse
    Zhuohua Wang
    Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 60612 7231, USA
    Endocrinology 146:5188-96. 2005
    ..These results indicate that disruption of GH signaling significantly inhibits prostate carcinogenesis...
  54. pmc Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice
    Shixia Huang
    Program in Cancer Biology and Genetics, Sloan Kettering Institute, New York, NY 10021, USA
    Genome Biol 6:R84. 2005
    ..These mice might therefore be useful models for discovering changes in gene expression during cancer development...
  55. ncbi request reprint Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling
    Xiao Zhang
    Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL 60612, USA
    Carcinogenesis 28:143-50. 2007
    ....
  56. pmc Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression
    Colin R Soares
    Department of Biology, Boise State University, Boise, ID 83725, USA
    Neoplasia 4:112-20. 2002
    ..These two novel cell lines will be useful for studying early stages of prostate tumor development and androgen responsiveness...
  57. ncbi request reprint Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models
    Masa Aki Shibata
    Department of Anatomy and Biology, Osaka Medical College, 2 7, Daigaku machi, Takatsuki, Osaka 569 8686, Japan
    Carcinogenesis 24:453-9. 2003
    ..The chemopreventive effects of lovastatin in vivo, however, may be tissue-specific...
  58. pmc Identification of tumor-initiating cells in a p53-null mouse model of breast cancer
    Mei Zhang
    Department of Molecular and Cellular Biology, Graduate program in Translational Biology and Molecular Medicine, and Lester and Sue Smith Breast Center of Baylor College of Medicine, Houston, Texas, USA
    Cancer Res 68:4674-82. 2008
    ..Furthermore, this p53-null mouse mammary tumor model may allow us to identify new CSC markers and to test the functional importance of these markers...
  59. ncbi request reprint Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model
    Ryan G Holzer
    Department of Biology, Boise State University, Boise, ID 83725, USA
    Breast Cancer Res Treat 77:65-76. 2003
    ..The development and characterization of a progressive series of new mammary carcinoma cell lines will aid in the study of mammary carcinoma progression both in vitro and in vivo...
  60. ncbi request reprint Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate
    Judith A Wubah
    Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, Maryland 21250, USA
    Prostate 51:21-9. 2002
    ..To elucidate genetic mechanisms that underlie prostate growth and development, we investigated differential gene expression in mouse prostate lobes...
  61. ncbi request reprint Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer
    Hirofumi Kawakubo
    Department of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Oncogene 23:8310-9. 2004
    ..Thus deregulation of BTG2 may be an important step in the development of mammary tumors...
  62. pmc Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
    Dalit Barkan
    Laboratory of Cell Biology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 68:6241-50. 2008
    ..Targeting this process may provide therapeutic strategies for inhibition of the dormant-to-proliferative metastatic switch...
  63. pmc Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways
    Sonal Datta
    Division of Cancer Biology and Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, IL 60201, USA
    Cancer Res 67:10286-95. 2007
    ....
  64. ncbi request reprint Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis
    Raul Catena
    Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pio XII 55, 31008 Pamplona, Spain
    Int J Cancer 120:2096-109. 2007
    ..Our results underscore the importance of VEGF(121) in human prostate carcinoma and demonstrate that the relative expression of the different VEGF isoforms has an impact on prostate carcinogenesis...
  65. ncbi request reprint Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:327S-330S. 2004
  66. ncbi request reprint Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells
    Ahmad Utomo
    Department of Biological Chemistry, School of Medicine, University of California, Irvine 92697, USA
    J Biol Chem 279:43522-9. 2004
    ..Thus, NPGPx plays an essential role in breast cancer cells in alleviating oxidative stress generated from polyunsaturated fatty acid metabolism...